Since PPARα and SIRT1 are downregulated and PARP1 is upregulated in NAFLD patients, the study of this interaction is of high importance for the treatment of the disease [17,101,102]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.